Intralytix
Intralytix is a Columbia, Maryland-based biotechnology company founded in 1998 that develops and commercializes bacteriophage-based products for food safety, pet food, nutraceutical, and clinical therapeutic applications, holding the world's largest portfolio of FDA/USDA-approved phage products.
- Company typePrivate
- Founded1998
- HeadquartersBaltimore, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Intralytix does
Intralytix is a privately held biotechnology company founded in 1998 in Baltimore (now headquartered in Columbia, Maryland) that develops, manufactures, and commercializes bacteriophage-based products for food safety, pet food safety, dietary supplements, and human therapeutics. Its technology uses naturally occurring lytic bacteriophages to selectively target and kill specific pathogenic bacteria such as Listeria monocytogenes, Salmonella, Shiga toxin-producing E. coli (STEC), Shigella, and Campylobacter in food processing environments, as well as to modulate the human microbiome for gut, oral, skin, and urinary tract health. The company holds the world's largest portfolio of FDA- and USDA-approved phage products — five food safety products plus the first FDA CVM-approved pet food phage (SalmoLyze) — and operates the largest U.S. cGMP manufacturing capacity for FDA-approved bacteriophage products under 21 CFR 117, supported by the only SQF certification in the phage industry. Three Phase 1/2a clinical trials (EcoActive for Crohn's disease, ShigActive for dysentery, VRELysin for VRE) target human therapeutic applications.
Intralytix generates revenue through direct sales of approved phage products to food processing companies, pet food manufacturers, and nutraceutical brands (via its [email protected] channel and 1-877-ITX-PHAGE line), supplemented by licensing/partnership agreements (e.g., Life Extension for VMS products) and grant funding (NIH P01, Maryland Manufacturing 4.0). Product development is powered by two proprietary AI/robotics platforms — PhageSelector for optimal phage cocktail design and PhageEngine for scaling phage-host growth dynamics to commercial cGMP production. The company achieved profitability in 2024, an uncommon milestone in the phage industry, following 800% cumulative growth in food safety product sales over 7-8 years and 76% YoY revenue growth from 2023 to 2024.
The customer base is concentrated in food processing verticals (ready-to-eat meats, poultry, seafood, produce, dairy), with secondary segments in pet food manufacturing, dietary supplement brands, and clinical research institutions. Go-to-market is enterprise field sales-led with technical application support, complemented by industry conference presence (Viruses of Microbes, ASM, Microbiome R&D Forums) and scientific publication-driven thought leadership. Geographic markets are currently limited to the United States, Canada, and Israel. Recent strategic moves include partnerships expanding into nutraceuticals (Life Extension, October 2025) and agriculture (Plaza Feed, December 2025), the FDA CVM approval for SalmoLyze (September 2025), and multimillion-dollar grant funding from NIH (June 2026) and the Maryland Department of Commerce (February 2026) to advance phage therapy and AI-driven manufacturing.
Intralytix firmographics
Firmographics- Name
- Intralytix
- Legal name
- Intralytix, Inc.
- Website
- https://intralytix.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Intralytix is a Columbia, Maryland-based biotechnology company founded in 1998 that develops and commercializes bacteriophage-based products for food safety, pet food, nutraceutical, and clinical therapeutic applications, holding the world's largest portfolio of FDA/USDA-approved phage products.
- Ownership category
- akta.pro rank
Intralytix industry classification
Industry- Product category
- Bacteriophage-based food safety and biocontrol products
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Food Manufacturing (311), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Bacteriocins & Biopreservatives (Nisin, Natamycin, Pediocin) (AFAJAFAG)
- akta.pro secondary industries
- Preservatives & Antimicrobials (Sorbates, Benzoates, Natamycin, Cultured Dextrose) (CRADAOAF), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)
Keywords
Where Intralytix is headquartered
LocationHeadquarters
- HQ city
- Baltimore
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Intralytix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure
Revenue model
- Product Sales: Direct sales of FDA/USDA-approved bacteriophage products for food safety applications including ListShield™, SalmoFresh™, EcoShield™ PX, ShigaShield™, CampyShield™. Also pet food safety products and dietary supplements.
- Partnership Agreements: Revenue from industry partnership agreements including collaborations with Life Extension for VMS products and other commercial partnerships.
- Grant Funding: NIH grants (multimillion-dollar P01 grant for phage therapy research), Maryland Manufacturing 4.0 grants for AI-ML driven phage manufacturing development.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Intralytix product offering
Product offeringCore offering
Intralytix discovers, manufactures, and markets bacteriophage-based biological products that selectively kill targeted bacterial pathogens in food, pet food, environmental, nutraceutical, and human therapeutic applications. The company holds the world's largest portfolio of FDA- and USDA-approved phage products and operates the largest U.S. cGMP manufacturing capacity for FDA-approved bacteriophage preparations. Revenue is driven by direct sales of approved biocontrol products (food safety, pet food) and the advancement of clinical-stage phage therapies.
Product overview
Intralytix offers the world's largest portfolio of FDA- and USDA-approved bacteriophage-based products across three main segments: Food Safety (ListShield™, SalmoFresh™, EcoShield™ PX, ShigaShield™, CampyShield™), Pet Food Safety (SalmoLyze®, PetShield, ListPhage™, Ecolicide®, Ecolicide® PX), and Dietary Supplements/Nutraceuticals (FortiPhage™, PhageBiotix™ GI, PhageBiotix™ UTS, PhageBiotix™ TRiP, SuperBiotix™ UTS, FortiPhage™ Plus, StaphLyse™). The company is also advancing Human Therapeutics with three Phase 1/2a clinical trials (EcoActive™ for Crohn's disease, ShigActive™ for Shigellosis, VRELysin™ for VRE). Product development is powered by proprietary AI platforms PhageSelector™ and PhageEngine™ for cocktail optimization and manufacturing scale-up.
Differentiator
Problem solved
Functional benefit
Brands
- ListShield: FDA-approved bacteriophage product targeting Listeria monocytogenes contamination in foods and food processing facilities
- SalmoFresh
- EcoShield
- PhageBiotix
- SuperBiotix
- PhageEngine
- PhageSelector
- SalmoLyze
- EcoActive
- ShigActive
- VRELysin
Products and services
- ListShield™ FDA- and USDA-approved bacteriophage preparation targeting Listeria monocytogenes contamination in foods and food processing facilities. First phage product to receive FDA approval worldwide. GRAS affirmed (GRN 528) for direct application to meat, poultry, fish, shellfish, fruits, vegetables, and dairy products, and listed under FSIS Directive 7120.1 as a safe and suitable processing aid.
- SalmoFresh™ FDA-cleared bacteriophage preparation targeting Salmonella enterica contamination in foods and food processing facilities. Targets multiple pathogenic serotypes including Typhimurium, Enteritidis, Heidelberg, Newport, Hadar, Kentucky, and others. GRAS affirmed (GRN 435) for poultry, fish, shellfish, fruits, vegetables, and other applications.
- EcoShield™ PX FDA-cleared bacteriophage preparation targeting Shiga toxin-producing Escherichia coli (STEC), including O157:H7 and all 'big six' STEC serotypes. FDA GRAS affirmed (GRN 834) and FCN 1018 for red meat processing; FSIS-listed as safe and suitable processing aid.
- ShigaShield™ Bacteriophage preparation targeting Shigella species contamination in foods and food processing facilities. FDA GRN 672 approved for direct application to foods.
- CampyShield™ Bacteriophage preparation targeting Campylobacter species and Campylobacter jejuni in foods and food processing facilities. FDA GRN 966 approved.
- SalmoLyze® FDA CVM-approved Salmonella-specific bacteriophage preparation for use as a processing aid to control Salmonella enterica in pet food and pet food ingredients. First phage product authorized by FDA CVM for pet food applications.
- PetShield Bacteriophage preparation targeting Shiga-toxin producing E. coli (STEC), Salmonella, and Listeria monocytogenes contamination in pet food.
- ListPhage™ Bacteriophage preparation targeting Listeria monocytogenes contamination in pet food.
- Ecolicide® Bacteriophage preparation targeting Escherichia coli O157:H7 contamination in pet food.
- Ecolicide® PX Pre-harvest intervention bacteriophage preparation targeting Escherichia coli O157:H7 contamination on hides of live animals.
- PhageBiotix™ FOP Complex phage preparation containing 9 to 15 lytic bacteriophages targeting L. monocytogenes, Salmonella spp., and Shiga-toxin producing E. coli (STEC) for food safety applications.
- FortiPhage™ Dietary supplement composed of three Myoviridae bacteriophages designed to maintain healthy gut microflora. Non-GMO, 100% natural product supporting daily digestive health and replenishing phages in the GI tract.
- PhageBiotix™ GI Advanced bacteriophage blend formulated for enhanced support of healthy gut microflora. Part of the patented PhageBiotix™ platform for microbiome modulation.
- PhageBiotix™ UTS Bacteriophage-based product designed to help maintain healthy gut and urinary tract microflora.
- PhageBiotix™ TRiP Bacteriophage product formulated to support healthy gut microflora during travel.
- SuperBiotix™ UTS Bacteriophage-based dietary supplement combining traditional probiotic cultures with PhageBiotix™ phage preparations to maintain healthy gut and urinary tract microflora.
- FortiPhage™ Plus Bacteriophage-based product combining FortiPhage™ with probiotics for enhanced gut microflora support.
- StaphLyse™ Bacteriophage product designed to support healthy microflora; also available as part of skin care program Revitalyse®.
- EcoActive™ Bacteriophage therapy targeting adherent-invasive E. coli (AIEC) in Crohn's disease patients. Currently in Phase 1/2a clinical trial at Mount Sinai Hospital and Johns Hopkins University. ClinicalTrials.gov NCT03808103.
- ShigActive™ Bacteriophage therapy targeting Shigella for treating dysentery. Phase 1/2a clinical trial at University of Maryland Center for Vaccine Development. ClinicalTrials.gov NCT05182749.
- VRELysin™ Bacteriophage therapy targeting vancomycin-resistant Enterococci colonization in the gastrointestinal tract. Phase 1/2a clinical trial at UPMC Pittsburgh. ClinicalTrials.gov NCT05715619.
- Life Extension Phage-based Nutraceutical Co-developed phage-based nutraceutical with Life Extension for the vitamins, minerals, and supplements (VMS) market, expanding bacteriophage technology into evidence-based health and wellness formulations.
Quantifiable outcome
- 99-99.9% reduction in targeted bacteria in foods
- +3 more outcomes
Companies that use Intralytix
Customer profileSegments4 records
Ideal customer profiles4 records
Intralytix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Intralytix partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- University of PittsburghcoreNIH P01 grant partnership through Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP). Joint initiative to develop phage therapy for multidrug-resistant Pseudomonas aeruginosa infections. Co-PI Dr. Alexander Sulakvelidze from Intralytix with collaborators from University of Pittsburgh, Walter Reed Army Institute of Research, USC, and Florida International University.
- Plaza Feed & Crop NutritioncoreCollaboration on a new bacteriophage kit for agricultural and microbiological applications. Focus on developing phage-based solutions for the agricultural sector.
- Life ExtensioncoreCollaboration to co-develop and commercialize a leading-edge phage-based nutraceutical for the vitamins, minerals, and supplements (VMS) sector. Aims to expand the role of bacteriophage technology within the health and wellness market, establishing a framework for evidence-based, phage-powered nutraceutical formulations.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Intralytix competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Intralytix social profiles
Digital presenceIntralytix compliance and trust
Trust signalCompliance11 records
Intralytix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Intralytix leadership team
Management profileNumber of profiles
Profiles9 records
Intralytix funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Intralytix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Intralytix
What does Intralytix do?
Intralytix discovers, manufactures, and markets bacteriophage-based biological products that selectively kill targeted bacterial pathogens in food, pet food, environmental, nutraceutical, and human therapeutic applications. The company holds the world's largest portfolio of FDA- and USDA-approved phage products and operates the largest U.S. cGMP manufacturing capacity for FDA-approved bacteriophage preparations. Revenue is driven by direct sales of approved biocontrol products (food safety, pet food) and the advancement of clinical-stage phage therapies.
Is Intralytix a public or private company?
Intralytix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Intralytix founded?
Intralytix was founded in 1998. It employs 11 to 50 people.
Where is Intralytix based?
Intralytix is headquartered in Baltimore, United States, in the North America region.
How does Intralytix make money?
Three revenue lines are on record. Product Sales are the primary driver. The others are partnership Agreements and grant Funding.
Does Intralytix have an API?
No public API is recorded for Intralytix.
What industry is Intralytix in?
Intralytix's product category is Bacteriophage-based food safety and biocontrol products. Its primary akta.pro industry code is AFAJAFAG, Bacteriocins & Biopreservatives (Nisin, Natamycin, Pediocin), with a secondary code of CRADAOAF, Preservatives & Antimicrobials (Sorbates, Benzoates, Natamycin, Cultured Dextrose). Its NAICS code is 325414 and its SIC code is 2836.